Submited on: 01 Jun 2017 10:25:38 PM GMT
Published on: 05 Jun 2017 09:36:32 AM GMT
Student review
Posted by Mr. Eric Gettler on 01 Nov 2017 01:33:11 AM GMT Reviewed by Interested Peers

  • What are the main claims of the paper and how important are they?

    The claims of this paper that TKI's are important oncology drugs that have made their way onto the market but there are some problems with them. There are drug-drug interactions (DDI's) that can affect the efficacy of the therapy as well as induce adverse drug responses. This paper also claims to create a concise resource for oncologists to use when prescribing TKI's so they can avoid common DDI's

  • Are these claims novel? If not, please specify papers that weaken the claims to the originality of this one.

    The claim of creating a list of common DDI's involving TKI's is a novel claim. I could not easily find a similar resource making this one an original, novel creation. 

  • Are the claims properly placed in the context of the previous literature?

    The claims are properly placed in the context that there are not many availible drug interaction resources regarding this class of anti cancer medications. 

  • Do the results support the claims? If not, what other evidence is required?

    The results do support the claims, the paper stated the presence of a concise resource used to help oncologists prescribe anti cancer drugs such as TKI's in conjunction with other possible offending drugs and there is a concise, but comprehensive list of DDI's availible for a clinician to look at. The interactions are further broken down in separate categories such as CYP induction/inhibition, drugs that affect the heart and QTc interval, gastric pH, and more. 

  • If a protocol is provided, for example for a randomized controlled trial, are there any important deviations from it? If so, have the authors explained adequately why the deviations occurred?

    There is no experimental protocol since no experiments were performed. This was paper is predominantly the amalgamation of TKI's and their common drug interactions compiled into a single document. 

  • Is the methodology valid? Does the paper offer enough details of its methodology that its experiments or its analyses could be reproduced?

    There are no experiments performed in this paper so there is no methodology to be followed. 

  • Would any other experiments or additional information improve the paper? How much better would the paper be if this extra work was done, and how difficult would such work be to do, or to provide?

    Perhaps the presence of experimental data would help reinforce the claims about interactions where there is no or very little amounts of data availible. 

  • Is this paper outstanding in its discipline? (For example, would you like to see this work presented in a seminar at your hospital or university? Do you feel these results need to be incorporated in your next general lecture on the subject?) If yes, what makes it outstanding? If not, why not?

    I would like to see this paper presented in a seminar, it would present a powerful tool that can optimize a clinicians time and efficiency to focus less on researching DDI's and more on other pressing issues. Additionally, having all of the common DDI's on one resource makes the clinician less likely to miss a drug interaction by mistake. 

  • Other Comments:


  • Competing interests:
  • Invited by the author to review this article? :
  • Have you previously published on this or a similar topic?:
  • References:


  • Experience and credentials in the specific area of science:

    Pharmacy student with some knowledge on pharmacokinetics and drug-drug interaction

  • How to cite:  Gettler E .Student review[Review of the article 'Tyrosine kinases inhibitors: interactions and safe use ' by Una Cidon E].WebmedCentral 2017;8(11):WMCRW003372
1 2 3 4 5 6 7 8 9
Report abuse